Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy.
June 25, 2025
by PR Newswire
Macrogen Consortium win tender for National Bio Big Data Project
Macrogen and Illumina Inc. (NASDAQ: ILMN) announced today that they are honoured to support the National Bio Big Data project by sequencing and analysing 145,952 Korean genomes.
December 23, 2024
by PRNewswire
FDA Authorizes First Next Generation Sequence Test for Diagnosing COVID-19
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) to Illumina, for the first COVID-19 diagnostic test utilizing next generation sequence technology.
June 22, 2020
by americanpharmaceuticalreview
New partnership to sequence human genomes in fight against coronavirus
As of this morning – Wednesday May 13 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 226,463 with 32,692 deaths.
May 13, 2020
by pharmatimes
Roche and Illumina partner to broaden patient access to genomic testing
Roche has entered into a 15-year, non-exclusive partnership with Illumina to broaden the adoption of distributable next-generation sequencing (NGS) based testing in oncology.
January 15, 2020
by worldpharmanews
Illumina expands Genomics Accelerator to Cambridge, UK
During two, six-month funding cycles per year, Illumina Accelerator provides selected startups with access to seed investment, access to Illumina sequencing systems and reagents, as well as business guidance, genomics expertise, and fully operational lab
July 17, 2019
by biospectrumasia
Illumina reports financial results for first quarter of FY 2019
Research and development (R&D) expenses for the first quarter of 2019 were $169 million compared to $137 million in the prior year period.
April 29, 2019
by biospectrumasia
Illumina receives 1st approval in China for its MiSeqDx sequencing system
With a certificate from the China National Drug Administration, Illumina has begun encouraging more clinical laboratories to choose the MiSeqDx system to develop new clinical assays.
August 30, 2018
by fiercebiotech
Illumina’s stock rides wave of high demand for genomic sequencing
High demand for genomic sequencing across the biotech industry drove Illumina to record revenues this past quarter, outperforming expectations and boosting the company’s stock price by over 7% in premarket trading.
August 1, 2018
by fiercebiotech